United Therapeutics is rated Buy with a base valuation of $535 per share, despite recent revenue declines caused by competition from Liquidia's Yutrepia. The company's main growth driver remains Tyvaso DPI, with declines limited to older drug formulations. Important upcoming events include FDA reviews for treatments of idiopathic pulmonary fibrosis (IPF) and Ralinepag, which could lead to label expansions and new product launches, potentially boosting the stock. Investors should watch litigation outcomes and quarterly Tyvaso DPI growth, with buying recommended if the price falls below $450.
United Therapeutics and its recent market context are provided here for readers. For those following the health sector, as of Sep 27, 2026 22:02 WIB, 54 of 100 priced US health-sector stocks on Pluang rose while 46 fell. Notable movers include RXRX at USD 3.74 with a 3.86% decline and 100% buy order activity, FLNA at USD 0.75 down 3.20% with 57% sell orders, and ENVB at USD 1.50 down 2.91%.
Accuray Incorporated announced a collaboration with Samsung NeuroLogica to develop advanced volumetric imaging capabilities for the CyberKnife System, aiming to improve treatment efficiency and decision-making in radiation therapy. This partnership c...
A recent $387.5 million theft from Bitget showed that native coins like XRP cannot be frozen by issuers, unlike stablecoins such as USDC and USDT, where issuers froze about $320,000. This difference arises because native coins have no central issuer ...
PNC Financial Services and U.S. Bancorp both beat earnings estimates but saw stock declines. PNC raised its dividend by 18%, offering stronger income growth, while U.S. Bancorp has a more diversified revenue mix and higher returns. PNC's loan book sh...
Quantum computers could eventually break Bitcoin's elliptic-curve cryptography, risking wallet theft—a scenario called "Q-Day." While no such quantum computer exists yet, the threat timeline is shrinking, prompting advances in three defense areas: qu...
Ripple is hosting an XRP event in Seoul on October 3, 2026, featuring major Korean banks like Woori Bank, Kyobo Securities, and Kakao Bank. The event will focus on tokenization, crypto payments, and decentralized finance (DeFi), highlighting Ripple's...
